Categories: CancerHealthcareNews

Erasca to Present at Upcoming Investor Conferences in November

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings.

Jefferies London Healthcare Conference (November 14 – 16, 2023)
Location: Waldorf Hilton, London, UK
Format: Fireside Chat
Date and Time: Wednesday, November 15, 2:30-2:55 PM GMT
Webcast: https://wsw.com/webcast/jeff287/eras

6th Annual Evercore ISI HealthCONx Conference (November 28 – 30, 2023)
Location: Kimpton Epic Hotel, Miami, FL
Format: Fireside Chat
Date and Time: Tuesday, November 28, 11:15-11:35 AM ET
Webcast: https://wsw.com/webcast/evercore39/eras

An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

59 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

1 hour ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

1 hour ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

1 hour ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

1 hour ago